Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Biological effects of phytoestrogens: clinical effectiveness and potential application in the treatment of climacteric syndrome

https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.020

Full Text:

Abstract

Aim. To review scientific publications on clinical effectiveness and potential application of phytoestrogens (PE) in the treatment of climacteric syndrome.

Materials and methods. The PRISMA approach was used. The systematic search was performed in three electronic scientific databases: Cochrane library, PubMed/MEDLINE, and eLIBRARY.ru. The publications were also manually searched for in the reference lists of the relevant articles.

Results. The filters were used to select 79 publications; 26 of them were included in the final review. The main method of treatment for the manifestations of the climacteric syndrome is menopausal hormonal therapy (MHT). One of the alternative methods for the control of its symptoms is the application of phytoestrogens (PE), primarily, isoflavones, lignans, and coumestans. Active metabolites of PE are expressed under the influence of gut microflora that is different in various groups of women, which can determine the differences in the effectiveness. Taking into account multidirectional character of the studies as well as numerous publications of low quality, it is still impossible to come to the final conclusion on the effectiveness of PE-containing food supplements (FS) when it comes to a decrease in the occurrence rate and expression of such symptoms as hot flushes, night sweats, and cognitive deterioration. The conclusions on the prevention of cardio-vascular diseases are not definite either.

Conclusions. The review showed that scientists could not come to the conclusion on the effectiveness and safety of PE-containing FS. Probably, the most prospective means of the control of climacteric syndrome are FS that contain isoflavones of red clover and soy in the maximum effective concentration. Considering free access to such FS on the market, they must meet high safety requirements.

About the Authors

M. A. Chernyavskaya
Saint-Petersburg Chemical Pharmaceutical University
Russian Federation

graduate student of the Department of Management and Economics of Pharmacy

14 Prof. Popova Str., Saint-Petersburg 197376, Russia

 



I. A. Narkevich
Saint-Petersburg Chemical Pharmaceutical University
Russian Federation

Dr Sci (Pharmaceutical Sciences), Professor, Rector & Head of the Department of Management and Economics of Pharmacy 

14 Prof. Popova Str., Saint-Petersburg 197376, Russia



References

1. Retail audit DSM.ru [Elektronnyi resurs]. URL: http.//www.dsm.ru/. Accessed: 24 marta 2020 g.

2. Baber R. J., Panay N., Fenton A. IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016; 19 (2): 109–150.

3. Hodis H. N., Collins P., Mock W. J., et al. The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Climacteric. 2012; 12: 217–28.

4. Schierbeck L. L., Rejnmark L., Tofteng C. L., et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomized trial. BMJ. 2012; 345: e6409.

5. Tarasova M. A., Yarmolinskaya M. I. The principles of individual choice of hormone replacement therapy in peri- and postmenopausal women. Practical guide for doctors. SPb. 2011; 5–6, 35–37 (in Russ).

6. Chester R.C., Kling J.M., Manson J.E. What the Women’s Health Initiative has taught us about menopausal hormone therapy. Clin Cardiol. 2018; 41 (2): 247–252. DOI: https://doi.org/10.1002/clc.22891.

7. Pines A. Women’s Health Initiative and rate of hormone use: a study that impacted a whole generation. Menopause. 2018; 25 (6): 586–588. DOI: https://doi.org/10.1097/GME.0000000000001071.

8. Crawford S. L., Crandall C. J., Derby C. A., et al. Menopausal hormone therapy trends before versus after 2002: impact of the Women’s Health Initiative Study Results. Menopause. 2018; 26 (6): 588–597. DOI: https://doi.org/10.1097/GME.0000000000001282.

9. Yureneva S. V., Il’ina L. M. The efficacy and safety of alternative treatments for menopausal symptoms in the light of recent evidence. Meditsinskii sovet. 2015; 20: 19–14 (in Russ).

10. Radzinskii V.E., Ordiyants I.M. Treatment of menopausal menopause. Rossiiskii meditsinskii zhurnal. 2018; 5 (I): 40–37 (in Russ).

11. Rietjens IMCM, Louisse J., Beekmann K. The potential health effects of dietary phytoestrogens. Br J Pharmacol. 2017; 174 (11): 1263–1280. DOI: https://doi.org/10.1111/bph.13622.

12. Jargin S. V. Soy and phytoestrogens: possible side effects. Ger Med Sci. 2014; 12: Doc18. DOI: https://doi.org/10.3205/000203.

13. Bilal I., Chowdhury A., Davidson J., Whitehead S. Phytoestrogens and prevention of breast cancer: The contentious debate. World J Clin Oncol. 2014; 5 (4): 705–712. DOI: https://doi.org/10.5306/wjco.v5.i4.705.

14. Smirnova T. V., Bril’ Yu. A. Phytoestrogens and cancer prevention. The protective effect of isoflavones on the mammary gland. News bulletin. Status Praesen. 2016; 1–13 (in Russ).

15. Kolátorová L., Lapčík O., Stárka L. Phytoestrogens and the intestinal microbiome. Physiol Res. 2018; 67 (Suppl 3): S401–S408. DOI: https://doi.org/10.33549/physiolres.934022.

16. Landete J. M., Gaya P., Rodríguez E., et al. Probiotic Bacteria for Healthier Aging: Immunomodulation and Metabolism of Phytoestrogens. Biomed Res Int. 2017; 2017: 5939818. DOI: https://doi.org/10.1155/2017/5939818.

17. Choi E.J., Kim G.H. The antioxidant activity of daidzein metabolites, O desmethylangolensin and equol, in HepG2 cells. Mol Med Rep. 2014; 9 (1): 328–332. DOI: https://doi.org/10.3892/mmr.2013.1752.

18. Wei X. J., Wu J., Ni Y. D., Lu L. Z., Zhao R. Q. Antioxidant effect of a phytoestrogen equol on cultured muscle cells of embryonic broilers. In Vitro Cell Dev Biol Anim. 2011; 47 (10): 735–741. DOI: https://doi.org/10.1007/s11626-011-9464-x.

19. Mayo B., Vázquez L., Flórez A.B. Equol: A Bacterial Metabolite from The Daidzein Isoflavone and Its Presumed Beneficial Health Effects. Nutrients. 2019; 11 (9): 2231.DOI: https://doi.org/10.3390/nu11092231.

20. Křížová L., Dadáková K., Kašparovská J., Kašparovský T. Isoflavones. Molecules. 2019; 24 (6): 1076. DOI: 10.3390/molecules24061076.

21. Alfa H. H., Arroo R. R.J. Over 3 decades of research on dietary flavonoid antioxidants and cancer prevention: What have we achieved? Phytochem Rev. 2019; 18: 989–1004. DOI: https://doi.org/https://doi.org/10.1007/s11101-019-09632-0.

22. Ko J. H., Sethi G., Um J. Y., et al. The Role of Resveratrol in Cancer Therapy. Int J Mol Sci. 2017; 18 (12): 2589. DOI: https://doi.org/10.3390/ijms18122589.

23. Dull A.M., Moga M.A., Dimienescu O.G., Sechel G., Burtea V., Anastasiu C.V.. Therapeutic Approaches of Resveratrol on Endometriosis via Anti-Inflammatory and Anti-Angiogenic Pathways. Molecules. 2019; 24 (4): 667. DOI: https://doi.org/10.3390/molecules24040667.

24. Khamoshina M. B., Bril’ Yu.A. Menopausal disorders: the variability of therapeutic approaches. News bulletin. Status Praesens. 2014; 12–14 (in Russ).

25. Tikhomirov A. L., Kazenashev V. V., Yudina T. A. Modern nonhormonal correction of menopausal disorders. Meditsinskii sovet. 2016; 12: 105–102 (in Russ).

26. Shikh E. V., Grebenshchikova L.Yu. Rational subsidization of micronutrients as a way to improve the quality of life in patients with menopausal syndrome. Meditsinskii sovet. 2017; 13: 171–166.

27. Lethaby A., Marjoribanks J., Kronenberg F., Roberts H., Eden J., Brown J. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database of Systematic Reviews. 2013; 12. Art. No.: CD001395. DOI: https://doi.org/10.1002/14651858.CD001395.pub4.

28. Apteka.ru. [Elektronnyi resurs]. URL: https://apteka.ru/. Acessed: 16.12.2019.


For citation:


Chernyavskaya M.A., Narkevich I.A. Biological effects of phytoestrogens: clinical effectiveness and potential application in the treatment of climacteric syndrome. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2020;13(2):164-169. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.020

Views: 147


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)